Form 4: Amneal Pharmaceuticals Executive Vice President & CFO, Tasos Konidaris, Sells 100,000 Shares

Tasos Konidaris, Executive Vice President & CFO of Amneal Pharmaceuticals, sold 100,000 shares of Class A Common Stock on March 5, 2025, at an average price of $8.91 per share.

Summary

• On March 5, 2025, Tasos Konidaris, the Executive Vice President & CFO of Amneal Pharmaceuticals, sold 100,000 shares of Class A Common Stock.
• The sale was executed at a weighted average price of $8.91 per share, with individual transactions ranging from $8.84 to $8.98.
• Following the reported transaction, Konidaris directly owns 621,882 shares of Amneal Pharmaceuticals.
• The reporting person has undertaken to provide full information regarding the number of shares sold at each separate price within the specified range upon request to Amneal Pharmaceuticals or the SEC staff.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of stock sale. The sale itself doesn't necessarily indicate a positive or negative outlook, but rather a personal financial decision.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity. It provides transparency into the transactions of company executives and their holdings in the company. Investors often monitor these filings to gain insights into management's perspective on the company's stock and future prospects.

Stakeholder Impact

• Shareholders may interpret the stock sale as a lack of confidence in the company's future performance, although it could also be due to personal financial reasons.

Key Dates